Cargando…

Central CB(2) receptors in inflammation-driven neurodegeneration: dysregulation and therapeutic potential

Detalles Bibliográficos
Autores principales:	Concannon, Ruth M., Dowd, Eilís
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5090836/ https://www.ncbi.nlm.nih.gov/pubmed/27857737 http://dx.doi.org/10.4103/1673-5374.191208

Ejemplares similares

Brain repair for Parkinson’s disease: is the answer in the matrix?
por: Moriarty, Niamh, et al.
Publicado: (2018)

cGMP signaling: a potential therapeutic target for neurodegeneration in glaucoma?
por: Holden, Joseph M., et al.
Publicado: (2022)

The Structure–Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation
por: Bow, Eric W., et al.
Publicado: (2016)

CB2 and GPR55 Receptors as Therapeutic Targets for Systemic Immune Dysregulation
por: Zhou, Juan, et al.
Publicado: (2016)

Sigma-2 receptor as a potential therapeutic target for treating central nervous system disorders
por: Terada, Kazuki, et al.
Publicado: (2019)

ULK1 as a novel therapeutic target in neurodegeneration
por: Vahsen, Björn Friedhelm, et al.
Publicado: (2020)

Editorial: Therapeutic potential of the cannabinoid CB2 receptor
por: Smoum, Reem, et al.
Publicado: (2022)

Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration
por: Galán-Ganga, M., et al.
Publicado: (2021)

Protective potential of glucagon like peptide 2 (GLP-2) against the neurodegeneration
por: Amato, Antonella, et al.
Publicado: (2019)

Synthetic cell pathobiology to study neurodegeneration: defining new therapeutic targets in astroglia
por: Stenovec, Matjaž, et al.
Publicado: (2016)

Nuclear peroxisome proliferator activated receptor-gamma (PPARγ) as a therapeutic target to treat neurodegeneration and dependence elicited by drugs of abuse
por: Ciccocioppo, Roberto, et al.
Publicado: (2020)

Oxidative stress in N88S seipinopathy: novel insights into the mechanisms of neurodegeneration and therapeutic avenues
por: Costa, Vítor, et al.
Publicado: (2022)

Neurotrophin receptors, gamma-secretase inhibitors, and neurodegeneration of basal forebrain cholinergic neurons
por: Vilar, Marçal
Publicado: (2021)

ERp57 in neurodegeneration and regeneration
por: Bargsted, Leslie, et al.
Publicado: (2016)

Oligomers and Neurodegeneration: New Evidence
por: Forloni, Gianluigi
Publicado: (2023)

Vascular inflammation in the central nervous system
por: Guo, Xinying, et al.
Publicado: (2022)

Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential
por: Vuic, Barbara, et al.
Publicado: (2022)

Transforming growth factor β1-mediated anti-inflammation slows progression of midbrain dopaminergic neurodegeneration in Parkinson's disease?
por: Spittau, Björn
Publicado: (2015)

Neurodegeneration in branch retinal vein occlusion
por: Alshareef, Rayan A., et al.
Publicado: (2016)

DNA damage and neurodegeneration: the unusual suspect
por: Stein, Daniel, et al.
Publicado: (2017)

Olfactory proteotyping: towards the enlightenment of the neurodegeneration
por: Fernández-Irigoyen, Joaquín, et al.
Publicado: (2019)

Immune dysregulation in extranodal NK/T cell lymphomas: potential roles in pathogenesis and immunotherapy
por: Polprasert, Chantana, et al.
Publicado: (2021)

Transient Receptor Potential Ankyrin 1 Channels in Inflammation and Cancer: Accelerators or Brakes?
por: Peng, Shuang
Publicado: (2022)

Shifting balance from neurodegeneration to regeneration of the brain: a novel therapeutic approach to Alzheimer's disease and related neurodegenerative conditions
por: Iqbal, Khalid, et al.
Publicado: (2014)

Sigma-1 receptor and neuroprotection: current outlook and potential therapeutic effects
por: Li Volti, Giovanni, et al.
Publicado: (2016)

The CB(2) receptor and its role as a regulator of inflammation
por: Turcotte, Caroline, et al.
Publicado: (2016)

New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders
por: Kibret, Berhanu Geresu, et al.
Publicado: (2022)

Cannabigerol Action at Cannabinoid CB(1) and CB(2) Receptors and at CB(1)–CB(2) Heteroreceptor Complexes
por: Navarro, Gemma, et al.
Publicado: (2018)

Dysregulation of protein trafficking in neurodegeneration
por: Wang, Xin, et al.
Publicado: (2014)

Neurodegeneration and neuroinflammation: two processes, one target
por: Carriba, Paulina, et al.
Publicado: (2015)

Dendrite pathology and neurodegeneration: focus on mTOR
por: Di Polo, Adriana
Publicado: (2015)

Metabolism, neurodegeneration and epigenetics: emerging role of Sirtuins
por: Silberman, Dafne M.
Publicado: (2018)

Mitochondrial bioenergetics and neurodegeneration: a paso doble
por: Rossi, Alice, et al.
Publicado: (2020)

CD8(+) T cells in neurodegeneration: friend or foe?
por: Hu, Dan, et al.
Publicado: (2022)

Cannabinoid CB2 Receptor Potentiates Obesity-Associated Inflammation, Insulin Resistance and Hepatic Steatosis
por: Deveaux, Vanessa, et al.
Publicado: (2009)

Diterpenes and the crosstalk with the arachidonic acid pathways, relevance in neurodegeneration
por: Zolezzi, Juan M., et al.
Publicado: (2019)

Neurogenesis versus neurodegeneration: the broken balance in Alzheimer’s disease
por: Polis, Baruh, et al.
Publicado: (2020)

Elucidating the pathological mechanisms of neurodegeneration in the lethal serpinopathy FENIB
por: Miranda, Elena, et al.
Publicado: (2022)

Novel perspectives for neurodegeneration prevention: effects of bioactive polyphenols
por: Crispi, Stefania, et al.
Publicado: (2020)

SIGMAR1 Confers Innate Resilience against Neurodegeneration
por: Couly, Simon, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kes5jjh0k5jjn41vhqirevqgo3